New and innovative therapies for Behcet's disease

APLAR Journal of Rheumatology

Volumn 7, Issue 2, 2004, Pages 141-145

  Davatchi, Fereydoun ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti TNF; Behcet's disease; Interferon ; Pentoxifylline; Pimecrolimus

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHOLERA TOXIN B SUBUNIT; COLCHICINE DERIVATIVE; CYCLOSPORIN; CYTOTOXIC AGENT; DAPSONE; ETANERCEPT; INFLIXIMAB; LEVAMISOLE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PEPTIDE 336-351; PEPTIDE DERIVATIVE; PIMECROLIMUS; PREDNISOLONE; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

APHTHOUS STOMATITIS; ARTHROPATHY; ATOPIC DERMATITIS; BEHCET DISEASE; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EYE DISEASE; FLU LIKE SYNDROME; GENITAL ULCER; HUMAN; IMMUNOLOGICAL TOLERANCE; INJECTION SITE REACTION; IONTOPHORESIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RASH; REMISSION; SKIN ULCER; UVEITIS;

EID: 23444436557     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2004.00074.x     Document Type: Conference Paper

References (30)

1. Davatchi F, Shahram F (2000) Epidemiology of Behcet's disease in Middle East and Asia. In: Bang D, Lee ES, Lee S eds. Behcet's disease S. Lee Publishers, Korea, 581-3.
2. Davatchi F (1998) Behcet's disease. In: Howe HS, Feng PH eds. Textbook of clinical rheumatology National Arthritis Foundation, Singapore, 298-315.
3. Davatchi F, Shahram F, Chams C, et al. (2003) Non-ocular manifestations of Behcet's disease. In: Zierhut M, Ohno S eds. Immunology of Behcet's disease. Swets and Zeitlinger B.V., Lisse, The Netherlands, 21-35.
4. Davatchi F (2003) Treatment of ocular manifestations of Behcet's disease. Adv Exp Med Biol 528, 487-91.
5. Tsambaos D, Eichelberg D, Goos M (1986) Behcet's syndrome treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278, 335-6.
6. Kotter I, Gunaydin I, Treush M, Zierhut M, Kanz L, Stubiger N (2003) The use of interferon-α in Behcet's Disease-Review of the literature and possible mechanisms of action. Adv Exp Med Biol 528, 503-9.
7. Aral A, Onder M, Gurer MA (2003) A case of Behcet's disease with pathergy reaction at Interferon injection site. Adv Exp Med Biol 528, 541-3.
8. Kotter I, Zierhut M, Eckstein A, et al. (2003) Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 528, 521-3.
9. Boyvat A, Sisman-Solak C, Gurler A (2000) Long-term effects of interferon alpha 2A treatment in Behcet's disease. Dermatology 201, 40-3.
10. O'Duffy JD, Calamia K, Cohen S, et al. (1998) Interferon-alpha treatment of Behcet's disease. J Rheumatol 25, 1938-44.
11. Melikoglu M, Fresko I, Mat C, et al. (2002) Etanercept is beneficial in controlling the mucocutaneous lesions of Behcet's Syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate crystals: a double blind placebo controlled trial. Arthritis Rheum 46, S206, (Abstract) 471.
12. Melikoglu M, Ozvazgan y Fresko I, et al. (2002) The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-α blocker, etanercept: an open study. Arthritis Rheum 46, S181, (Abstract) 400.
13. Sablé-Fourtassou R, Wechsler B, Bodaghi B, Cassoux N, LeFloang P, Piette JC (2002) Infliximab in refractory panuveitis due to Behcet's disease. 10th International Conference on Behcet's Disease, Berlin. 100, Abstract 175.
14. Triolo G, Ciccia F, Ferrante A (2002) Effect of infliximab in tile treatment of Behcet's disease unresponsive to standard therapy. Report of three cases. 10th International Conference on Behcet's Disease, Berlin. 100, Abstract 176.
15. Joseph A, Raj D, Dua HS, Powellt PT, Lanyon PC, Powelit RJ (2002) Infliximab in the treatment of refractory posterior uveitis associated with Behcet's syndrome. 10th International Conference on Behcet's Disease, Berlin. 101, Abstract 177.
16. Morris DS, Gavin MP, Sturrock RD (2003) The effect of anti-tumor necrosis alpha (Infliximab) on sight-threatening uveitis in a patient with Behcet's disease. Adv Exp Med Biol 528, 557-9.
17. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. (2001) Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 358, 295-6.
18. Katsiari CG, Theodissiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis PP (2003) Successful long-term treatment of refractory adamantiades-Behcet's disease with infliximab: Report of two patients. Adv Exp Med Biol 528, 551-5.
19. Behrens F, Zollner T, Moeller B, Kaltwasser JP, Kaufmann R, Ochsendorf F (2002) Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behcet's disease. 10th International Conference on Behcet's Disease, Berlin. 101, Abstract 180.
20. Mussack T, Landauer N, Ladurner R, et al. (2003) Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 98, 703-4.
21. Kram MT, May LD, Goodman S, Molinas S (2003) Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46, 118-21.
22. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 120, 995-9.
23. Lehner T, Stanford MR, Phipps PA, et al. (2003) Immunopathogenesis and prevention of uveitis with the Behcet's disease-specific peptide linked to cholera toxin B. Adv Exp Med Biol 528, 173-80.
24. Stanford MR, Whittall T, Balarajah G, Lindblad M, Holmgren J, Lehner T (2002) Phase 1 trial of oral tolerisation with heat shock protein peptide linked to cholera toxin b subunit in the treatment of Behcet's disease (BD). 10th International Conference on Behcet's Disease, Berlin. 69, Abstract 50.
25. Liang GC, Chang EM (2003) Pentoxifylline use for Behcet's Disease. Adv Exp Med Biol 528, 591-4.
26. Triolo G, Accardo Palumbo A, Ciccia F, et al. (2002) In vitro effect of pentoxifylline on Vgama9/Vdelta2 T lymphocytes in Behcet's disease. 10th International Conference on Behcet's Disease, Berlin. 103. Abstract. 188.
27. BenEzra D, Cohen E, Halhal M, Behar-Cohen F (2002) Treatment of Behcet's ocular manifestations by iontophoresis. 10th International Conference on Behcet's Disease, Berlin. 104, Abstract 190.
28. Gupta A, Chow M, Pimecrolimus: A, (2003) Review. J Eur Acad Dermatol Venereol 17, 493-503.
29. Graham-Brown RA, Grassberger M (2003) Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 57, 319-27.
30. Ruzika T, Assmann T, Lebwohl M (2003) Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol 13, 331-42.